Specialty Pharma Journal Specialty, Precision & Technology
SAN DIEGO, Dec. 18, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc., an innovator in predicting disease …
Tag Archives: Biocept
December, 2018
August, 2018
-
6 August
Biocept to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs
SAN DIEGO, Aug. 6, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into an agreement with a large integrated healthcare delivery network to …
July, 2018
-
25 July
Biocept and UC San Diego Moores Cancer Center Partner to Study Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy
SAN DIEGO, July 23, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will work with Moores Cancer Center at UC San Diego Health to conduct two clinical studies in patients with …
June, 2018
-
18 June
Published Case Report Demonstrates the Clinical Utility of Biocept’s CTC Platform in Metastatic Breast Cancer
SAN DIEGO, June 18, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed case report demonstrating the clinical utility of its …
January, 2018
-
11 January
Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Detection of Lung Cancer Biomarkers
SAN DIEGO, Jan. 9, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that incorporation of the Thermo Fisher QuantStudio5 (QS5) real-time PCR instrument into the …
August, 2017
-
18 August
Biocept and UT Southwestern Medical Center Announce Study to Profile & Monitor NSCLC Cancer Patients with ALK Rearrangements
SAN DIEGO, Aug. 17, 2017 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces it has entered into a clinical study agreement with the University of Texas Southwestern Medical …
May, 2015
-
4 May
Biocept Launches its c-MET Biomarker
Molecular oncology diagnostics company, Biocept, Inc., is expanding its cancer diagnostic portfolio with the launch of a new liquid biopsy detection test. The company announced the launch of its c-MET amplification detection test utilizing a blood-based “liquid biopsy.” According to the company, the diagnostic assay can potentially help physicians identify …